Xencor | XNCR - Actif À Court Terme





Actif À Court Terme Changement Date
AbbVie USD 29.06B 523M 2025-12
Alnylam Pharmaceuticals USD 4.22B 168.65M 2026-03
Amgen USD 31.48B 2.42B 2026-03
Arrowhead Research USD 1.17B 223.75M 2025-12
AstraZeneca USD 29.61B 890M 2026-03
Biogen USD 9.19B 216.3M 2026-03
Bristol-Myers Squibb USD 27.21B 2.18B 2026-03
Cytokinetics USD 839.46M 77.51M 2026-03
GlaxoSmithKline GBP 17.76B 251M 2026-03
J&J USD 59.17B 3.55B 2026-03
Karyopharm Therapeutics USD 103.15M 13.4M 2025-12
MacroGenics USD 219.94M 12.15M 2025-12
Merck USD 35.02B 8.5B 2026-03
Novartis USD 26.61B 3.85B 2026-03
Pfizer USD 42.82B 76M 2026-03
Regeneron Pharmaceuticals USD 18.21B 187.3M 2026-03
Roche Holding CHF 38.73B 3.03B 2025-12
Xencor USD 599.82M 81.38M 2025-12